BRPI0620629B8 - composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso - Google Patents

composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso

Info

Publication number
BRPI0620629B8
BRPI0620629B8 BRPI0620629A BRPI0620629A BRPI0620629B8 BR PI0620629 B8 BRPI0620629 B8 BR PI0620629B8 BR PI0620629 A BRPI0620629 A BR PI0620629A BR PI0620629 A BRPI0620629 A BR PI0620629A BR PI0620629 B8 BRPI0620629 B8 BR PI0620629B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
acid
dihydroxypt
methylsulfonyl
Prior art date
Application number
BRPI0620629A
Other languages
English (en)
Inventor
Naversnik Klemen
Tomaz Jaklic Miha
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0620629A2 publication Critical patent/BRPI0620629A2/pt
Publication of BRPI0620629B1 publication Critical patent/BRPI0620629B1/pt
Publication of BRPI0620629B8 publication Critical patent/BRPI0620629B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição farmacêutica. a presente invenção refere-se a uma formulação quimicamente estável de ácido (e)-7-[4-(4-fiuorofenil)-6-isopropil-2-[metil(metilsulfonil) amino]pirimidin-5-il]-(3r, 5s)-3,5-diidroxiept-6-enóico ou um sal farmaceuticamente aceitável do mesmo para uso oral, tais como comprimidos, cápsulas, pôs, grânulos que foi desenvolvida utilizando as substâncias que se estabilizam contra a formação de produtos de degradação: lactona e produto de oxidação.
BRPI0620629A 2005-12-20 2006-12-18 composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso BRPI0620629B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200500344 2005-12-20
SIP200500344 2005-12-20
PCT/EP2006/012180 WO2007071357A2 (en) 2005-12-20 2006-12-18 Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid

Publications (3)

Publication Number Publication Date
BRPI0620629A2 BRPI0620629A2 (pt) 2011-11-16
BRPI0620629B1 BRPI0620629B1 (pt) 2020-01-14
BRPI0620629B8 true BRPI0620629B8 (pt) 2021-05-25

Family

ID=37866173

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620629A BRPI0620629B8 (pt) 2005-12-20 2006-12-18 composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso

Country Status (9)

Country Link
US (1) US20090093499A1 (pt)
EP (1) EP1968593B1 (pt)
JP (1) JP5235676B2 (pt)
CN (1) CN101330919B (pt)
AU (1) AU2006329006B2 (pt)
BR (1) BRPI0620629B8 (pt)
CA (1) CA2630704C (pt)
EA (1) EA015682B1 (pt)
WO (1) WO2007071357A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
JP2011510974A (ja) * 2008-01-30 2011-04-07 ルピン・リミテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤の調節放出製剤
EA024554B1 (ru) * 2008-06-27 2016-09-30 Крка, Товарна Здравил, Д.Д., Ново Место Твердая лекарственная форма, содержащая розувастатин, и способ ее получения
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
RU2606592C1 (ru) * 2015-10-07 2017-01-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
IL292929A (en) * 2019-12-31 2022-07-01 Pfizer R& D Uk Ltd Stable immediate-release tablet and capsule formulations of 1-((s2,r5)-5-((h7-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2 -an-1-on

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
CA2440641A1 (en) * 2001-03-13 2002-09-19 Anand R. Baichwal Chronotherapeutic dosage forms containing glucocorticosteroid
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
WO2003080023A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2003092729A1 (de) * 2002-05-03 2003-11-13 Hexal Ag Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1689723B1 (en) * 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
EP1737828A1 (en) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin
EP1709008A1 (en) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof

Also Published As

Publication number Publication date
AU2006329006B2 (en) 2013-02-28
EA200801447A1 (ru) 2008-12-30
US20090093499A1 (en) 2009-04-09
BRPI0620629B1 (pt) 2020-01-14
CN101330919A (zh) 2008-12-24
CA2630704C (en) 2014-08-19
EP1968593A2 (en) 2008-09-17
JP2009519985A (ja) 2009-05-21
BRPI0620629A2 (pt) 2011-11-16
EP1968593B1 (en) 2017-08-23
WO2007071357A3 (en) 2007-11-08
AU2006329006A1 (en) 2007-06-28
EA015682B1 (ru) 2011-10-31
CN101330919B (zh) 2012-12-05
CA2630704A1 (en) 2007-06-28
WO2007071357A2 (en) 2007-06-28
JP5235676B2 (ja) 2013-07-10

Similar Documents

Publication Publication Date Title
BRPI0620629B8 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica e seu uso
BRPI0715712B8 (pt) composição farmacêutica adequada para a administração oral compreendendo um derivado de triazol[4,5d]pirimidina
CY1121782T1 (el) Διαδικασια για ξηρανση της bibw2992, tων αλατων αυτης και στερεων φαρμακευτικων σκευασματων που περιλαμβανουν αυτο το δραστικο συστατικο
EA017764B8 (ru) Фармацевтическая композиция, способ ее получения и способ лечения вирусных заболеваний с ее использованием
AR023624A1 (es) Composiciones farmaceuticas que comprenden un inhibidor de hmg coa reductasa
TW200711652A (en) Method and composition for pharmaceutical product
EA201100032A1 (ru) Соединения пиридина
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
TW200800998A (en) Phenylalanine derivatives
CY1109756T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικα αλατα 7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2- [μεθυλ(μεθυλσουλφονυλ)αμινο] πυριμιδιν-5-υλ]-(3r,5s)-3,5-διυδροξυεπτ-6-ενοϊκου οξεος
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
NZ595127A (en) Stable pharmaceutical composition for atherosclerosis
BRPI0514735B8 (pt) derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
PH12019502566A1 (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a] pyrimidine derivatives
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
BR112014011981A2 (pt) formulações farmacêuticas
WO2008074833A3 (en) Compounds
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
AR022462A1 (es) Uso de un agente que disminuye el colesterol
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
EA200970708A1 (ru) Фармацевтические композиции, включающие аторвастатин и никотиновую кислоту

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.